{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-24-000030","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.683190+00:00","generated_at":"2026-06-04T22:51:12.747055+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M","bullets":["Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.","Biologics & drug delivery revenue $13.6M in 2023, +49% YoY; gross margin 57% (down from 66%).","Cash & equivalents $23.1M at Dec 31; Q4 cash burn reduced to $1.2M.","Reaffirmed 2024 revenue guidance $28M-$32M; early 2024 milestones include 6 new hospitals, FDA clearance, ~$15M equity offering.","Operating expenses $36.1M in 2023 (up from $29.9M), driven by higher headcount and share-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-24-000030","json":"https://secwatch.observer/filing/0001285550-24-000030.json","markdown":"https://secwatch.observer/filing/0001285550-24-000030.md","text":"https://secwatch.observer/filing/0001285550-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/0001285550-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/clpt-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:51:12.747055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3babfbd2fed77dd4c1ae331b038a529368c64ade","claim":"ClearPoint Neuro, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $6.8 million. Guidance reaffirmed.","evidence_excerpt":"Reported fourth quarter 2023 revenue of $6.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/0001285550-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$6.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eff57661ee7ffd7c957890d0ae9de25e0c0fda3f","claim":"ClearPoint Neuro, Inc. reported the fiscal year ended December 31, 2023 results: revenue $24.0 million. Guidance reaffirmed.","evidence_excerpt":"Reported revenue of $24.0 million for the full year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/0001285550-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$24.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}